Compare ORI & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORI | RDY |
|---|---|---|
| Founded | 1923 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 9.9B |
| IPO Year | 1994 | 2001 |
| Metric | ORI | RDY |
|---|---|---|
| Price | $39.91 | $14.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $43.50 | $14.79 |
| AVG Volume (30 Days) | 1.6M | ★ 2.4M |
| Earning Date | 10-22-2026 | 10-23-2026 |
| Dividend Yield | ★ 9.49% | 0.43% |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.62 | N/A |
| Revenue | ★ $9,136,300,000.00 | N/A |
| Revenue This Year | $6.83 | $4.58 |
| Revenue Next Year | $5.72 | $11.95 |
| P/E Ratio | ★ $10.94 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.65 | $11.36 |
| 52 Week High | $46.76 | $15.67 |
| Indicator | ORI | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 67.85 |
| Support Level | $37.11 | $12.91 |
| Resistance Level | $40.72 | $15.08 |
| Average True Range (ATR) | 0.80 | 0.26 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 53.54 | 75.86 |
Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.